For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Gilead Sciences (GILD) is a stock that can certainly grab the ...

LEN is a first-in-class, long-acting HIV-1 capsid inhibitor that disrupts multiple stages of the viral replication cycle. By ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology industry. Ideally, one might believe that Gilead Sciences Inc. might perform better in the ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...

Fueled by growth in its civil litigation business and government-facing practices, Wilmer's PEP rose more than 5% to $3.27 ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

Environmental science is the multidisciplinary study of all aspects of the Earth’s physical and biological environments. It encompasses environmental chemistry, soil science, ecology ...